Kardigan (KARD)
Develops cardiovascular therapies through biologically defined, data-enabled clinical trials.
Something off on this page? Send us feedback.
Develops three investigational cardiovascular drug programs for biologically defined patient groups and uses Prolaio to collect high-frequency physiologic data in trials; has no approved products or current revenue, and outsources manufacturing.
Develops investigational, precision cardiovascular treatments for biologically defined patient groups, using three lead programs aimed at genetic dilated cardiomyopathy, calcific aortic valve stenosis, and post-discharge acute severe hypertension. Danicamtiv, ataciguat, and tonlamarsen are all in recruiting clinical studies; their rights were licensed or acquired from other drug developers.
Combines the clinical portfolio with Prolaio, a platform that collects continuous physiologic data from wearable sensors and third-party devices to support adaptive trial decisions and digital-measure research. Operations span Princeton, South San Francisco, Chicago, and clinical sites in multiple countries. All manufacturing and trial execution depend on external partners, while Prolaio has not been validated by FDA to support regulatory decision-making for therapeutic candidates.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $597.6M · Total debt $13.3M · Total assets $721.8M · Shareholders' equity $615.5M
- Revenue
- $0
- Operating income
- −$75.2M
- Net income
- −$116.2M
No dividends on record.
| Institutions69 holders · as of Jun 30, 2026 | 61.19% | 57.22M shares | |
| Insiders2 holders · as of Aug 13, 2026 | 16.41% | 15.35M shares | |
| Otherremainder | 22.40% | 20.94M shares |
93.50M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
SCHF (Gpe), LLCInstitution | 18.09% | 16.92M | 13Fas of Jun 30, 2026 |
Gianakakos AnastasiosInsider | 11.20% | 10.47M | 13Gfiled Aug 13, 2026 ↗ |
FMR LLCInstitution | 9.53% | 8.91M | 13Fas of Jun 30, 2026 |
Perceptive Advisors LLCInstitution | 8.77% | 8.20M | 13Fas of Jun 30, 2026 |
Edelberg JayInsider | 5.22% | 4.88M | 13Gfiled Aug 13, 2026 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
Nothing filed in the last 12 months.
- Alnylam Pharmaceuticals
Closest drug-program overlap in hypertension via angiotensinogen lowering.
- Edwards Lifesciences
Procedural substitution through earlier TAVR in moderate valve disease.
- Cytokinetics
Cardiac-myosin activation in systolic heart failure.
- Rocket Pharmaceuticals
Gene therapy for BAG3-associated genetic DCM.
- AstraZeneca (ADR)
Approved aldosterone-synthase inhibition for hypertension.
- Novartis (ADR)
Monthly Lp(a) lowering in mild-to-moderate CAVS.
- Mineralys Therapeutics
Late-stage oral aldosterone inhibition for hypertension.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Kardigan | $21.82 | +11.33% | $1.96B | — | — | — | — |
| Alnylam Pharmaceuticals | $269.53 | +0.88% | $35.78B | 45.2 | 31.5 | 7.4 | +66.9% |
| Edwards Lifesciences | $90.90 | +0.10% | $52.29B | 52.2 | 28.9 | 8.0 | +13.6% |
| Cytokinetics | $71.93 | −0.12% | $8.95B | — | — | 126.1 | −57.1% |
| Rocket Pharmaceuticals | $3.80 | −1.55% | $421.5M | — | — | — | — |
| AstraZeneca (ADR) | $163.88 | +1.37% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Novartis (ADR) | $162.04 | −0.25% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Mineralys Therapeutics | $29.03 | −0.07% | $2.56B | — | — | — | — |
| Median | 34.8 | 23.1 | 7.4 | +6.4% |